Skip to main content
. 2018 Nov 6;9:649. doi: 10.3389/fendo.2018.00649

Figure 3.

Figure 3

Potential targets of GLP-1 receptor agonists in the treatment of NAFLD include: (A) a decrease in caloric intake through central regulation of satiety, (B) a reduction of hepatic and adipose tissue insulin resistance due to decrease in body weight, (a direct effect may not be excluded, dashed lines) (C) a modified intestinal lipoprotein metabolism, (D) a resolution of dysfunctional adipose tissue and (E) an enhancement of insulin release.